why choose us

First received: November 02, 2022

Clinical Trial: Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Neuroendocrine Tumor

Study Type: INTERVENTIONAL


Official Title: Preoperative PRRT Versus Surgical Cytoreduction Alone in Metastatic Pancreatic Neuroendocrine Tumors to the Liver: A Phase II Multi-institutional Trial

Brief Summary: Doctors and researchers leading this study hope to learn more about peptide receptor radionuclide therapy (PRRT) in combination with cytoreduction (surgically removing tumors).They hope to learn if combining PRRT in combination with cytoreduction would be more effective than cytoreduction alone.PRRT itself is approved by the U.S. Food and Drug Administration (FDA) for people with PanNETs however the combination with cytoreduction is considered experimental.Your participation in this research will last about 2…

Read more